Five hypoglycaemic hyperinsulinaemic patients (three with proven benign insulinoma, one with proven metastasizing insulinoma, one with probable insulinoma not found at surgery) were treated with propranolol for a variable time ranging from two weeks to one year. Three patients showed favourable clinical results and a significant increase of the mean basal blood glucose level was found while two patients showed no improvement of the frequency of neuroglycopenic episodes and no significant increase of their mean basal blood glucose level. No patient showed a significant decrease in mean basal IRI concentration.
The beta adrenergic blocking agent propranolol is known to influence muscle and liver glycogenolysis as well as gluconeogenesis [1, 5] and to inhibit insulin secretion [6, 10] . Propranolol has been reported to cause hypoglycaemia in some animals and in debilitated diabetic persons or patients undergoing acute stress with a period of starvation [11] [12] [13] [14] [15] . Slight hyperglycaemia has been also reported in normal man [161 . It is possible that hypoglycaemia could be caused by inhibition of glycogenolysis and of counter-regulatory responses to low glucose levels in patients taking insulin or in starved persons [4, 5] . These subjects, unlike hypoglycaemic subjects with insulinoma, have extremely low insulin release, so that propranolol effects on splanchnic glucose production prevail. On the other hand hyperglycaemia could arise in normal persons from inhibition of insulin secretion induced by the drug.
In 1969, Neri et al. [17] first proposed the use of propranolol in order to reduce hypoglycaemic attacks in patients with functioning insulinoma. In 1972, some of us [18] reported the favourable results obtained in a patient with organic hyperinsulinism due to a metastasizing insulinoma. Recently Blum et al. [19] confirmed the usefulness of propranolol in the prevention of hypoglycaemic attacks in a patient with insulinoma.
The present report describes our experience with propranolol in five hypoglycaemic patients with organic hyperinsulinism.
Material and Methods
Five hypoglycaemic patients were treated with propranolol for a variable time ranging from two weeks to a one year. The clinical characteristics of the patients and the type and length of the treatment are reported in Table 1 . Patient No. 4 showed a typical syndrome of organic hyperinsulinism; nevertheless at surgery it was impossible to find the insulinoma. At the time of propranolol therapy, patients nos. 3 and 4 were already on treatment with [20] ] were determined before and during propranolol administration. Data obtained during the propranolol administration period were compared with those obtained in a similar period of time, immediately preceeding the treatment. In patients nos. 3 and 4, the determinations obtained during the therapy with chloropromazine alone were considered as a control.
In order to reduce as much as possible the time before surgery, it was considered proper to carry out only a few stimulatory tests in each patient. The tests performed are listed in Table 3 . All tests were carried out after 7-10 days of propranolol therapy.
In order to evaluate as a whole insulinaemic responses during the stimulatory tests, the incremental areas were measured. The values obtained were then averaged dividing them by the duration of the test. The latter results were thus expressed as U/ml. min.
Statistical analysis of fasting blood glucose was carried out using Student's t-test. Plasma insulin data (non parametric distribution) were analysed by means of Mann and Whitney U-test.
Results
Mean + SEM of fasting blood glucose, average values and ranges of basal plasma insulin and frequency of hypoglycaemic attacks before and during propranolol administration are given in Table 2 .
After 1-3 days, propranolol treatment diminished the frequency of neuroglycopenic episodes in patients nos. 2, 4 and 5 and in these patients fasting blood glucose increased significantly. The other two patients (nos. 1 and 3) showed no improvement and the mean value of fasting blood glucose remained unchanged.
At the end of therapy, withdrawal of the drug caused rapid deterioration of the clinical status with reappearance of frequent hypoglycaemic episodes in two (nos. 2 and 4) of the three ameliorated patients. On the other hand, blood glucose remained within normal range for ten days after termination of therapy in patient no. 5, who did not suffer of hypoglycaemic symptoms during this period.
Changes of fasting plasma IRI were not related to the variations of frequency of neuroglycopenic symptoms in the treated patients and did not show statistically significant changes.
The tolbutamide and prolonged fasting tests, that had to be interrupted before propranolol administration owing to the appearance of neuroglycopenia, were both well tolerated during propranolol treatment. Glucose levels both basal and during IVGTT, tolbutamide and glucagon tests, were higher during propranolol therapy, whereas no relevant changes were observed during OGTT.
IRI concentration incremental areas found during stimulatory tests or prolonged fasting, are reported in Table 3 . As can be seen, mean plasma insulin response were clearly decreased during OGTT, IVGTT, tolbutamide and glucagon tests with propranolol therapy. During prolonged fasting insulin values tended to decrease during propranolol administration, whereas they were sligthly increased before treatment.
Discussion
The results of studies on the effect of adrenergic receptor affecting agents on B-cell function and on glycogenolysis are controversial and rather inconclusive. Propranolol reduces basal insulin secretion [21] as well as early phase of glucose-induced insulin release [22] . Conway and Eaton [2] [29] , in spite of the fact that propranolol abolishes glucagon-induced hyperglycaemia in rabbits [30] .
In three of our patients who were tested by OGTT, IVGTF, Glucagon, Tolbutamide or by fasting, IRI responses, as judged by incremental insulinaemic areas, were clearly decreased during propranolol treatment. However, propranolol administration did not result in a significant decrease of fasting peripheral plasma insulin levels, even in those patients who showed significant increases of fasting blood glucose levels. These observations suggest that propranolol induced improvement is not fully explainable by the inhibitory action of this drug on insulin release, as supposed before [17, 31] .
The possibility that propranolol increases blood glucose levels in patients with organic hyperinsulinism independently of variations of insulin secretion should be considered. An increase of growth hormone release after beta adrenergic blockade [24, 32-34] may contribute to the modifications of carbohydrate metabolism. Moreover it is still argued as to whether glycogenolysis is an alpha or beta adrenergic effect and Antonis et al. [35] and Day [5] have affirmed that epinephrine-induced hepatic glucose production is mediated by alpha receptors. Since beta adrenergic blockade may relatively increase alpha adrenergic effect, propranolol could raise hepatic glycogenolysis.
The ratio between proinsulin like components and total IRI in plasma of patients with islet cell tumours is higher than in normal subjects [36] [37] [38] . The possibility that propranolol may affect this ratio in the material secreted by the insulinoma cells could explain the improvement of blood glucose without significant variations of immunoassayable substances in plasma. However this hypothesis is at present only speculative, since relevant data on this point are missing.
In conclusion, the improvement of basal clinical status induced by propranolol therapy may result from probably hepatic changes of glucose metabo- a Treated with propranolol + chloropromazine. Value "before" refers to a test performed in a treatment period with chloropromazine alone lism that are yet not well understood and that leave altogether unchanged the peripheral levels of insulin.
On the other hand, inhibition of insulin secretion seems to represent the main way by which improvement of metabolic situation during physiological or pharmacological stimulation is achieved. From a clinical point of view, propranolol treatment may be useful in some hypoglycaemic patients.
